Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
AbCellera Biologics
ABCL
AbCellera Biologics
Clinical And Regulatory Risks Will Limit Upside Despite Potential Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
10 Aug 25
Updated
16 Aug 25
1
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$5.00
12.2% undervalued
intrinsic discount
16 Aug
US$4.39
Loading
1Y
68.2%
7D
-4.4%
Author's Valuation
US$5.0
12.2% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$5.0
12.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-166m
507m
2018
2020
2022
2024
2025
2026
2028
Revenue US$37.1m
Earnings US$4.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
36.66%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.95%
Calculation
US$4.75m
Earnings '28
x
400.88x
PE Ratio '28
=
US$1.90b
Market Cap '28
US$1.90b
Market Cap '28
/
311.69m
No. shares '28
=
US$6.10
Share Price '28
US$6.10
Share Price '28
Discounted to 2025 @ 6.95% p.a.
=
US$4.99
Fair Value '25
